Oral bisphosphonate use tied to lower endometrial cancer risk

Oral bisphosphonate use tied to lower endometrial cancer risk

(HealthDay)—For postmenopausal women, oral bisphosphonate use is associated with a reduction in the risk of endometrial cancer, according to a study published online Feb. 23 in the Journal of Clinical Oncology.

Polly A. Newcomb, Ph.D., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues examined the correlation between oral bisphosphonate use and the risk of in a cohort of 89,918 . At baseline, a detailed health interview was conducted, and an inventory of regularly used medications was reviewed to ascertain bisphosphonate use at baseline and during follow-up.

The researchers found that 1,123 women were diagnosed with incident invasive endometrial cancer during a median follow-up of 12.5 years. There was a reduction in the risk of endometrial cancer with ever use of bisphosphonates (adjusted hazard ratio, 0.8; 95 percent confidence interval, 0.64 to 1; P = 0.05); no interactions were seen with age, , or indication for use.

"In summary, our findings suggest that use of bisphosphonates is modestly associated with reduced endometrial cancer risk, a finding consistent with the inverse association between use of this medication and ," the authors write.

One author disclosed financial ties to the pharmaceutical industry.


Explore further

Soy food, isoflavone intake not linked to endometrial cancer

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Clinical Oncology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Oral bisphosphonate use tied to lower endometrial cancer risk (2015, March 2) retrieved 25 August 2019 from https://medicalxpress.com/news/2015-03-oral-bisphosphonate-tied-endometrial-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more